TF and cancer: Some studies have found TF+EVs to co-express CD41 leading to speculation that tumour EVs may bind to platelets, then be re-shed as TF+platelet EVs [41,52], and suggesting that levels of TF activity in a combined platelet and EV sample may be a more accurate measure of thrombotic risk in patients with cancer compared with the TF activity of tumour EVs alone.